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Abstract
Purpose—Aging is a poor prognostic factor for melanoma. We have shown that melanoma cells 
in an aged microenvironment, are more resistant to targeted therapy than identical cells in a young 
microenvironment. This is dependent on age-related secreted factors. Klotho is an age-related 
protein, whose serum levels decrease dramatically by age 40. Most studies on klotho in cancer 
have focused on the expression of klotho in the tumor cell. We have shown that exogenous klotho 
inhibits internalization and signaling of Wnt5A, which drives melanoma metastasis and resistance 
to targeted therapy. We investigate here whether increasing klotho in the aged microenvironment 
could be an effective strategy for the treatment of melanoma.
Experimental Design—PPARγ increases klotho levels, and is increased by glitazones. Using 
rosiglitazone, we queried the effects of rosiglitazone on Klotho/ Wnt5A crosstalk, in vitro and in 
vivo, and the implications of that for targeted therapy in young vs. aged animals.
Results—We show that rosiglitazone increases klotho and decreases Wnt5A in tumor cells, 
reducing the burden of both BRAF-inhibitor sensitive, and BRAF inhibitor-resistant tumors in 
aged, but not young mice. However, when used in combination with PLX4720, tumor burden was 
reduced in both young and aged mice, even in resistant tumors.
Conclusions—Using glitazones as adjuvant therapy for melanoma may provide a new treatment 
strategy for older melanoma patients who have developed resistance to vemurafenib. As klotho has 
been shown to play a role in other cancers too, our results may have wide relevance for multiple 
tumor types.
*To Whom Correspondence Should Be Addressed: Ashani T. Weeraratna, Ph.D., The Wistar Institute, Rm 452/454A, 3601 Spruce 
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Introduction
Dermal fibroblasts undergo age-related changes that result in altered secretory profiles. We 
have recently shown that these age-related changes can drive melanoma progression, and 
therapy resistance. We found that one of the ways in which the aged microenvironment 
promoted metastasis was via secretion of an inhibitor of canonical Wnt signaling, sFRP2. 
sFRP2 secreted by aged dermal fibroblasts suppressed β-catenin signaling in melanoma 
cells. The loss of β-catenin signaling has been associated with a increase in metastatic 
capacity of melanoma cells, as well as a decrease in sensitivity to vemurafenib. We found 
this to be true for melanoma cells in an aged microenvironment as well, such that the 
restoration of β-catenin signaling by anti-sFRP2 antibody in vivo re-sensitized tumors to 
vemurafenib, and decreased their metastatic ability. In melanoma, the secreted non-
canonical Wnt signaling molecule, Wnt5A, also drives the metastatic progression of 
melanoma (1) and resistance to targeted therapy, in part by inhibiting β-catenin signaling 
(2). Wnt5A is therefore significantly associated with poorer prognosis in melanoma. We 
have recently asked what factors might regulate Wnt5A, and we, and others, have identified 
the anti-aging hormone klotho as a regulator of Wnt signaling (3, 4).
Klotho is a circulating serum factor, which is lost during aging. Overexpression of klotho in 
transgenic mice promotes longevity (5). Conversely, the knockout of klotho results in a 
complex premature aging phenotype, where mice that are born phenotypically normal 
develop atherosclerosis, osteoporosis, skin atrophy and bone degeneration. Klotho has also 
been shown to decrease Wnt signaling (3). We discovered that Wnt5A is bound to the 
surface of melanoma cells by heparan sulfate proteogylcans (6), and klotho, which has 
sialidase activity (7), cleaves Wnt5A from the proteoglycans, such that it cannot be 
internalized and signal (4). Once this occurs, Wnt5A mRNA expression also decreases, as 
Wnt5A increases PKC, which in turn signals to stabilize Wnt5A mRNA. Klotho therefore 
affects both Wnt5A internalization and mRNA expression, and treatment of Wnt5A-high 
cells with recombinant klotho significantly inhibits their invasion (4).
In addition to its sialidase activities, klotho plays essential roles in maintaining phosphate 
homeostasis, inhibiting oxidative stress, suppressing cellular senescence and modulating 
insulin receptor signaling (8–11). The loss of klotho is thought to correspond either directly 
or indirectly to increased insulin resistance, which is associated with diabetes (5). Recently, 
there has been much interest in using anti-diabetic drugs to treat melanoma. Drugs such as 
metformin and phenformin have been suggested because they affect mitochondrial 
biogenesis and changes in mitochondrial biogenesis affect melanoma cell response to 
vemurafenib, and contribute to drug resistance (12, 13).
Another class of drugs used to treat diabetes is the glitazones, which are agonists of the 
peroxisome proliferator-activated receptor, PPARγ, a nuclear hormone receptor that controls 
the transcription of multiple genes involved in lipid biogenesis and metabolism (14). Klotho 
is a transcriptional target of PPARγ, such that PPARγ increases klotho mRNA (15). Wnt5A 
has recently been shown to inhibit expression of PPARγ via the activation of CAMKII (16). 
We previously reported that Wnt5A also inhibited klotho, largely at the mRNA level, but at 
the time did not have a mechanism by which it did so. We hypothesized that Wnt5A may be 
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able to repress klotho expression via CAMKII- mediated suppression of PPARγ. Here we 
test and confirm this hypothesis. We further show that using available PPARγ agonists, such 
as rosiglitazone (trade name Avandia), can increase serum levels of klotho in the blood and 
in the tumor microenvironment, and decrease Wnt5A. Intriguingly we also find that 
rosiglitazone decreases the growth of BRAF resistant melanomas in aged, but not young 
mice.
Methods
CELL CULTURE
WM858, WM793, WM164 and 1205LU cells were maintained in MCDB153 (Sigma, St 
Louis, MO)/ L-15 (Cellgro, Manassas, VA) (4:1 ratio) supplemented with 2% FBS and 1.6 
mM CaCl2 (Tumor growth media). WM983B cells were maintained in DMEM (Invitrogen, 
Carlsbad, CA), supplemented with 5% FBS, 100 units/ml penicillin and streptomycin and 4 
mM L-glutamine. The PLX4720 resistant cell lines were cultured in media same as the 
parent lines in presence of PLX4720 (Chemietek). FS5, FS4, cells were maintained in RPMI 
(Invitrogen, Carlsbad, CA), supplemented with 10% FBS, 100 units/ml penicillin and 
streptomycin and 4 mM L-glutamine. Yumm1.7 melanoma cells derived from the 
BRAFV600E/PTEN−/−/CDKN2A−/− mouse model of melanoma and human fibroblasts 
were maintained in DMEM, supplemented with 10% FBS, 100 units/ml penicillin and 
streptomycin and 4 mM L-glutamine. Yumm1.7 cells were cultured to resistance in 10μM 
PLX4720. Keratinocytes were maintained in keratinocyte SFM supplemented with human 
recombinant Epidermal Growth Factor 1–53 (EGF 1–53) and Bovine Pituitary Extract (BPE) 
(Invitrogen). All the cell lines were cultured at 37°C in 5% CO2. Cell stocks were 
fingerprinted using AmpFLSTR® Identifiler® PCR Amplification Kit from Life 
Technologies TM at The Wistar Institute Genomics Facility. Although it is desirable to 
compare the profile to the tissue or patient of origin, our cell lines were established over the 
course of 40 years, long before acquisition of normal control DNA was routinely performed. 
However, each STR profile is compared to our internal database of over 200 melanoma cell 
lines, as well as control lines, such as HeLa and 293T. STR profiles are available upon 
request. Cell culture supernatants were mycoplasma tested using a Lonza MycoAlert assay 
at the University of Pennsylvania Cell Center Services.
TREATMENTS
Cells were treated with 100 ng/ml of recombinant Wnt5A (R&D Systems, cat. no. 
645WN010CF) for 16 h or 10ng/ml of recombinant klotho (R&D Systems, cat. no. 5334-
KL-025 ) for 48 h. KN93 (Cayman, cat. no. 13319) was used at a final concentration of 
10μM and Rosiglitazone (Sigma-Aldrich, cat. no. R2408-50MG) at 10μM for 48 h unless 
otherwise stated. BRAF resistance subclones were seeded overnight in the absence of 
PLX4720 and then treated as indicated.
WESTERN BLOTTING
Western blotting was done as described in (17). Briefly, total protein lysate of 50–65μg was 
run on 4–12% NuPAGE Bis Tris gel (Invitrogen, cat no. NW 041222BOX), transferred onto 
PVDF membrane using iBlot 2, Life technologies and blocked in 5%milk/TBST. To analyze 
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level of secretory klotho, conditioned media from fibroblasts was run on 4–12% NuPAGE 
Tris gel and total protein lysate from the fibroblasts was used to probe for HSP90 as loading 
control. Primary antibodies were used at the following concentrations: biotinylated Wnt5A 
(500 ng/ml; R&D Systems, cat. no. BAF645), Klotho (1:500; abcam, cat. no. ab98111), 
HSP90 (1:4000; Cell Signaling, cat. no. 4877S), CAMKII (1:500; Cell Signaling, cat. no. 
3362S), CAMKII alpha/delta (p Thr286) (1:500; NBP1-51462, Novus), pERK (1:500; Cell 
Signaling, cat no. 4370S), ERK (1:500; Cell Signaling, cat no. 4696S). All primary 
antibodies were diluted in 5% milk/TBST and incubated overnight at 4°C. The membranes 
were washed in TBST and probed with the corresponding HRP-conjugated secondary 
antibody (0.2–0.02 μg/ml of anti-mouse, streptavidin, or anti-rabbit). Proteins were 
visualized using ECL prime (Amersham, Uppsala, Sweden) or Luminata Crescendo 
(Millipore, Billerica, MA, USA).
ORGANOTYPIC 3D SKIN RECONSTRUCTS
Organotypic 3D skin reconstructs were generated as previously described (18). Briefly, 6.4 x 
104 fibroblasts were plated in each insert on top of the acellular layer (BD, cat. no. 355467 
and Falcon, cat. No. 353092) and incubated for 45 min at 37°C in a 5% CO2 tissue culture 
incubator. The tissue culture trays were filled with DMEM containing 10% FBS and 
incubated for 4 days. Reconstructs were then incubated for 1 h at 37°C in HBSS containing 
1% dialyzed FBS (wash media). Washing media was removed and replaced with reconstruct 
media. Keratinocytes (4.17 x 105) and melanoma cells (8.3 x 104) were added to the inside 
of each insert. Media was changed every other day until day 18, reconstructs were then 
harvested, fixed in 10% formalin, paraffin embedded, sectioned and stained.
IMMUNOHISTOCHEMISTRY (IHC)
Immunohistochemistry was performed on paraffin embedded sections as described 
previously (18). Briefly, Paraffin embedded sections were rehydrated through a xylene and 
alcohol series rinsed in H2O and washed in PBS. Antigen retrieval was performed by 
steaming for 20 min in target retrieval buffer (Vector Labs, Burlingame, CA) and steamed 
for 20 min. Samples were blocked in a peroxidase blocking buffer (Thermo Scientific) 
followed by Protein block (Thermo Scientific) and incubated in appropriate primary 
antibody diluted in antibody diluent (S0809, Dako) at 4°C overnight in a humidified 
chamber. Samples were then incubated in biotinylated anti-rabbit or polyvalent secondary 
antibody (Thermo Scientific) followed by streptavidin-HRP solution. Samples were then 
washed in PBS and incubated in 3-Amino-9-Ethyl-l-Carboazole (AEC) chromogen. Finally, 
samples were washed in H2O, incubated in Meyer’s hematoxylin for 1 min, rinsed in cold 
H2O, and mounted in Aquamount. Patient samples were collected under IRB exemption 
approval for protocol #EX21205258-1.
IMMUNOFLUORESCENCE (IF)
Cells were seeded onto glass cover slips and incubated overnight. These cells were then 
treated with fibroblast conditioned media, KN93 or Rosiglitazone with the indicated dose for 
48 h. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% TritonX-100, 
blocked with 1% BSA and stained for primary antibodies as previously described (18). 
When staining for klotho cells were not permeabilized. For immunofluorescence staining in 
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the 3D skin reconstructs, the paraffin embedded sections were rehydrated, processed for 
antigen retrival and blocked as described for IHC. Primary antibodies were used at the 
following concentrations: Klotho (1:150), PPARγ (1:100, abcam, cat. No. ab19481), 
Wnt5A (1:50), HMB45 (1:50, abcam, cat. No. ab787) and incubated at 4°C overnight. Cells 
were washed in PBS and incubated with the appropriate secondary antibody (1:2000, 
Invitrogen) for 1 h at room temperature and mounted in Prolong Gold anti-fade reagent 
containing DAPI (Invitrogen). Images were captured on a Leica TCS SP5 II scanning laser 
confocal system.
LENTIVIRAL INFECTION
shRNA against human klotho was obtained from Sigma-Aldrich, KL MISSION shRNA 
Bacterial Glycerol Stock. Klotho shRNA clones used were: TRCN0000158823 and 
TRCN0000160036. Lentiviral production was performed as described previously (18). 
Briefly, 293T cells were co-transfected with Klotho shRNA vector and lentiviral packaging 
plasmids (pCMV-dR8.74psPAX2, pMD2.G). The supernatant containing virus was 
harvested at 36 and 60 hours, combined and filtered through a 0.45μm filter and stored in 
−80 degrees till further use. For transduction, the cells were layered overnight with lentivirus 
containing 8 μg/ml polybrene. The cells were allowed to recover for 24 hours and then 
selected using 1μg/ml puromycin.
siRNA TRANSFECTION
KL siRNA and negative control siRNA (100nM, ambion) were transfected into cells using 
Lipofectamine 2000 (Thermo Fisher Scientific) as per manufacturer’s protocol.
MITOCHONDRIAL STAINING
Melanoma cells treated with indicated conditions were seeded onto a 384 well plate at 3000 
cells/well in triplicate (PerkinElmer cell carrier). For analyzing mitochondrial mass, cells 
were incubated with MitoTracker® Green FM (M7514, ThermoFisher Scientific) at 1μM 
concentration for 1 h. To analyze production of superoxide by mitochondria, cells were 
incubated with MitoSOX™ Red reagent (M36008, ThermoFisher Scientific) at a final 
concentration of 5μM for 10 min, washed extensively and were imaged using PerkinElmer 
Operetta. The fluorescent signal was quantified using Harmony 3.0 software. Readings were 
normalized to cell number which was determined by Hoescht staining (Hoechst 33342, 
Invitrogen). Cells seeded on coverslips were also stained with MitoTracker® Red CM-
H2Xros (M7513, Thermofisher Scientific) at 1μM concentration for 1 h, fixed with 
formaldehyde 4% and mounted in Prolong Gold anti-fade reagent. Images were captured on 
a Leica TCS SP5 II scanning laser confocal system. Fluorescence were normalized to cell 
number.
TCGA DATABASE ANALYSIS
The RNAseq and Clinical data set for skin cutaneous melanoma (19) was downloaded from 
TCGA (http://cancergenome.nih.gov/). Patient ages were group into 10 year age ranges. 
Patient sample information is included in Supplementary Table 1.
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REAL TIME PCR
RNA was extracted using Trizol (Invitrogen) and RNeasy Mini kit (Qiagen) as previously 
described (18). cDNA was prepared using iscript cDNA synthesis kit (Bio-Rad, cat. No. 
1708891). Gene expression was quantified using SYBR green method of qPCR and mRNA 
levels were compared to standard curves. qPCR was performed on an ABI StepOnePlus 
sequence detection system using fast conditions and samples were normalized against the 
18S gene, using Universal 18S primers (Invitrogen, cat. No. AM1718). Expression was 
calculated using the standard curve method according to the manufacturer’s protocol (Perkin 
Elmer, Waltham, MA). The sequences for primers are Klotho forward primer: 
GCTCTCAAAGCCCACATACTG; Klotho reverse primer: GCAGCATAACGATAGAGGCC 
Wnt5a forward primer: AGGGCTCCTACGAGAGTGCT; Wnt5a reverse primer: 
GACACCCCATGGCACTTG.
CELL VIABILITY ASSAY (MTS)
Cell viability was determined using CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay according to manufacturers protocol. Briefly, cells were seeded in flat bottom 96-well 
plates and allowed to adhere overnight. The next day, cells were treated with the indicated 
drugs for indicated time period. Following treatments, cells were incubated with MTS dye 
(20 μl/well) for 2 h. Absorbance was determined at 490nm using an EL800 microplate 
reader (BioTek, Winooski, VT). The percent cell viability was calculated by converting the 
experimental absorbance to percentage of control and plotted vs drug concentration. The 
values were then analyzed using a nonlinear dose-response analysis in GraphPad Prism.
IN VIVO TUMOR BURDEN ASSAY
All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) (IACUC #112503X_0) and were performed in an Association for the Assessment 
and Accreditation of Laboratory Animal Care (AAALAC) accredited facility. YUMM1.7 
parental or YUMM1.7_BR (2.5 x 105 cells) were injected subcutaneously into young (6 
week old) and aged (52 week old) C57/BL6 mice (Charles River). Tumor sizes were 
measured every 3–4 days using digital calipers, and tumor volumes were calculated using 
the following formula: volume = 0.5 x (length x width2). When resulting tumors reached 
200 mm3, mice were fed with either AIN-76A chow or AIN-76A chow containing 417 
mg/kg PLX4720. Time-to-Event (survival) was determined by a 5-fold increase in baseline 
volume (~1000 mm3) and was limited by the development of skin necrosis. For treatment 
with recombinant mouse Klotho (R&D systems, Cat. No. 1819KL) or Rosiglitazone, mice 
were injected intraperitoneally with recombinant Klotho, 0.02mg/Kg every 2 days or with 
Rosiglitazone, 10mg/Kg every other day. To analyze klotho levels in serum, serum was 
isolated from blood collected by sub-mandibular bleeding and Klotho levels were analyzed 
by western blotting. At the end of experiment mice were euthanized, tumors were harvested 
and a portion of the tumors were embedded in paraffin and sectioned.
STATISTICAL ANALYSIS
For in vitro studies, a Student’s t-test or Wilcoxon rank-sum test (Mann Whitney) was 
performed for two-group comparison. Estimate of variance was performed and parameters 
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for the t-test were adjusted accordingly using Welch’s correction. ANOVA or Kruskal-Wallis 
test with post-hoc Bonferroni’s or Holm-Sidak’s adjusted p-values was used for multiple 
comparisons. For in vivo studies, repeated measures analysis of variance (Anova) was 
calculated between samples. Holm Sidak correction was performed. For other experiments, 
Graphpad/Prism6 was used for plotting graphs and statistical analysis. Data was represented 
as +/− SEM. Significance was designated as follows: *, p<0.05; **, p<0.01; ***, p<0.001.
Results
Manipulation of klotho in dermal fibroblasts affects Wnt5A expression in melanoma cells
Klotho expression is decreased in aged human skin (Figure 1a). We have recently shown that 
aged dermal fibroblasts can drive the metastasis and therapeutic resistance of melanoma 
largely through secreted factors. To investigate if the loss of klotho from fibroblasts 
contributes to the increased aggression and therapy resistant phenotype of melanoma cells in 
the aged microenvironment, we assayed dermal fibroblasts derived from non-melanoma, 
healthy donors who were either young (25–35 years old) or aged (55–65 years old) for 
expression of klotho. All fibroblast experiments were normalized to cell number. As 
expected, aged dermal fibroblasts demonstrated a decrease in klotho expression as compared 
to young fibroblasts, as measured by RT-PCR, Western analysis, (Figure 1b,c), and 
immunofluorescent analysis (Supplementary Figure 1a). Further, klotho expression was also 
decreased in the serum of aged mice, as measured by ELISA (Supplementary Figure 1b). In 
skin reconstructs built with aged and young fibroblasts, young fibroblasts continued to 
express klotho, whereas aged fibroblasts did not (Supplementary Figure 1c). Melanoma 
cells, surprisingly, recapitulated the age-related klotho expression of fibroblasts: if young 
fibroblasts were present in the skin reconstruct, melanoma cells in the proximity also 
expressed klotho. If aged fibroblasts were present, melanoma cells expressed lower levels of 
klotho (Figure 1d). TCGA analysis of melanoma samples revealed that klotho is indeed 
decreased in melanoma patients as they age. The difference is most significant under 40 (the 
age where klotho is lost in the serum) and over 55 (where the incidence of melanoma 
increases rapidly), however expression decreases steadily by decade (Supplementary Figure 
1d, patient information provided in Supplementary Table 1).
Since we have previously shown that exogenous klotho affects Wnt5A internalization and 
expression, we asked whether differences in the amount of klotho secreted from young vs. 
aged fibroblasts affected Wnt5A accordingly in melanoma cells. To confirm that any effects 
observed were fibroblast-related, we treated melanoma cells with media from young and 
aged fibroblasts, as well as with un-conditioned media with and without 10% fetal bovine 
serum (FBS). As expected, in the melanoma cells treated with serum-free media, Wnt5A 
was elevated (Figure 1e). Consistent with our hypothesis, Wnt5A expression was low in 
melanoma cells treated with both serum-containing media and media from young 
fibroblasts. However, when we tested the serum-containing media for klotho we found that it 
contained klotho (data not shown). In contrast, aged fibroblast media resulted in an elevated 
level of Wnt5A expression (Figure 1e, Supplementary Figure 1e). Melanoma cells in aged 
fibroblast conditioned media also have less klotho mRNA as compared to the cells in young 
fibroblast conditioned media (Supplementary Figure 1 f).
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We next observed Wnt5A regulation by the aged microenvironment in artificial skin 
reconstructs made with young or aged fibroblasts, into which we put identical melanoma cell 
lines. As noted above (Figure 1d) melanoma cells recapitulate the klotho expression of the 
fibroblasts, such that melanoma cells in reconstructs made with young fibroblasts express 
klotho, and melanoma cells in reconstructs made with aged fibroblasts express less klotho. 
Consistent with our hypothesis that klotho modulates Wnt5A expression, in skin 
reconstructs made with aged fibroblasts and melanoma cells, Wnt5A was increased in 
melanoma cells, compared to identical skin reconstructs built with young fibroblasts (Figure 
1f, additional cell line, Supplementary Figure 1i, j). To determine whether this differential 
Wnt5A expression could be altered by manipulating klotho in young and aged fibroblasts, 
we knocked down klotho using sh_RNA against klotho (sh_klotho) in young fibroblasts 
(Supplementary Figure 1g, h) and observed an increase in Wnt5A in melanoma cells 
exposed to sh_klotho fibroblast media. Conversely, treating aged fibroblasts with 
recombinant klotho (rklotho) decreased Wnt5A in melanoma cells exposed to rklotho-
supplemented aged media (Figure 1g). We confirmed this result in skin reconstructs built 
using young fibroblasts treated with either a control (scrambled) shRNA, or with a klotho 
shRNA. In the reconstructs built with the klotho knockdown fibroblasts, the levels of klotho 
in the melanoma cells decrease (Figure 1h) and the level of Wnt5A increases (Figure 1i), 
mimicking the aged fibroblast conditions. Together these data indicate that the loss of klotho 
in the aged microenvironment, specifically in dermal fibroblasts, increases Wnt5A in 
melanoma cells. We have shown extensively that Wnt5A is involved in multiple aspects of 
tumor progression. Therefore, reconstitution of Wnt5A upon klotho loss during aging may 
be another mechanism leading to the increased aggression of melanoma in the elderly.
Wnt5A suppresses klotho via CAMKII mediated inhibition of PPARγ
We previously showed that Klotho acts as a sialidase, cleaving Wnt5A away from the 
surface of melanoma cells. We next wanted to determine the mechanism by which Wnt5A 
can regulate klotho. Klotho is a target of PPARγ, a regulator of fatty acid storage and 
glucose metabolism (15). PPARγ is phosphorylated and degraded by the activation 
(phosphorylation) of CAMKII, which in turn is a direct target of Wnt5A (16). Thus, we 
hypothesized that Wnt5A regulates klotho expression via CAMKII mediated degradation of 
PPARγ (outlined in Figure 2a). Indeed, treatment of melanoma cells with rWnt5A increased 
CAMKII phosphorylation (Figure 2b) and decreased PPARγ and klotho (Figure 2c). 
Conversely, when aged fibroblasts were treated with the CAMKII inhibitor KN93, mRNA 
expression of klotho was increased (Figure 2d), as was protein expression of PPARγ (Figure 
2e). Even at the highest doses, KN93 was not toxic to fibroblasts (Supplementary Figure 2a, 
b). To determine whether KN93 had similar effects on melanoma cells, we treated melanoma 
cells with KN93 (10μM, 48h) and demonstrated that PPARγ and klotho were restored 
(Figure 2f, g). Consistently, exploration of PPARγ expression levels in the TCGA database 
revealed that, like klotho, PPARγ levels were decreased in older melanoma patients 
(Supplementary Figure 2c, aged vs. young at different decades of life).
As our data above suggested that activation of PPARγ should increase klotho, and regulate 
Wnt5A, we treated aged fibroblasts with the PPARγ agonist rosiglitazone, which increased 
PPARγ, and klotho (Figure 2h, i). Melanoma cells treated with rosiglitazone demonstrated a 
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decrease in the secreted form of Wnt5A in the lysate (Supplementary Figure 2d, upper 
band). As in fibroblasts, we observed increases in both PPARγ and klotho in melanoma cells 
treated with rosiglitazone (Supplementary Figure 2e). Like KN93, Rosiglitazone was not 
toxic to either fibroblasts or melanoma cells at high doses (Supplementary Figure 2f, g). To 
translate these findings in vivo, we used Yumm1.7 melanoma cells derived from the 
BRAFV600E/PTEN−/−/CDKN2A−/− mouse model of melanoma, and injected them into 
C57BL/6 mice. When tumors were palpable, we treated one set of aged mice with 10mg/kg 
of rosiglitazone and one set with 0.02mg/kg of recombinant klotho, and treated a third set 
with PBS/DMSO vehicle control. Tumor burden was significantly reduced as compared to 
control by treatment with either rosiglitazone or recombinant klotho (Figure 2j). Treatment 
of aged mice with rosiglitazone or recombinant klotho decreased Wnt5A and increased 
klotho levels in the tumor (Figure 2k). Together these data suggest that using rosiglitazone as 
an agent to increase PPARγ and klotho can decrease Wnt5A and inhibit tumor growth in an 
aged microenvironment.
Rosiglitazone-mediated inhibition of Wnt5A can inhibit growth of BRAF-inhibitor resistant 
cells
One of the first line therapies for melanoma is the drug vemurafenib, which targets a mutant 
BRAF protein (BRAFV600E). Our previous work demonstrated that Wnt5A can promote 
resistance to targeted therapy in melanoma (2, 17), and we support this by showing that 
knockdown of Wnt5A can increase the sensitivity of melanoma cells to PLX4720, the tool 
compound for Vemurafenib (Supplementary Figure 3a, b). Further, Wnt5A is more highly 
secreted by aged as compared to young fibroblasts (Supplementary Figure 3c), which is in 
keeping with our previous data showing that melanomas in an aged microenvironment are 
more resistant to vemurafenib, largely due to changes in Wnt signaling (18). Importantly, it 
has been shown that Wnt5A can signal to activate ERK, and CAMKII, also a target of 
Wnt5A, activates the Raf signaling pathway further. This represents a way to maintain 
activation of the MAPK pathway, regardless of mutational status. To determine if 
manipulating this pathway in melanoma cells could affect resistance of melanoma cells to 
BRAF inhibition, we created a resistant subclone of Yumm1.7 cells that we could use in 
vivo. These subclones are as resistant in vitro to PLX4720 (the tool compound for 
vemurafenib) as are WM983B BRAF inhibitor-resistant subclones (Supplementary Figure 
4a). Next we analyzed the Yumm1.7, WM983B, WM793 and their resistant subclones for 
Wnt5A and PO4-ERK. Each of these cell lines bears a different set of mutations 
(Supplementary Table 2). In each case, both Wnt5A and PO4-Erk were elevated (Figure 3a). 
This was also concomitant with the loss of klotho and PPARg expression (Supplementary 
Figure 4b–f). We then asked whether increasing klotho via rosiglitazone reduced PO4-Erk 
signaling, via downregulation of Wnt5A. PO4-Erk is decreased in BRAF-resistant cell lines 
after treatment with rosiglitazone (Figure 3b) and this is concomitant with the decrease in 
Wnt5A (Supplementary Figure 4g). KN93 is similarly able to cause decreases in both PO4-
Erk and Wnt5A (Supplementary Figure 4h). We then asked whether transcriptionally 
silencing klotho would prevent rosiglitazone from decreasing ERK activity and decreasing 
Wnt5A. Knocking down klotho in young fibroblasts increased PO4-Erk and Wnt5A 
(Supplementary Figure 4i). In melanoma cells treated with rosiglitazone, there is a reduction 
of both Wnt5A and PO4-ERK. However, first knocking down klotho results in activated Erk, 
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and sustained Wnt5A signaling, even in the presence of rosiglitazone (Figure 3c, 
Supplementary Figure 4j). These data suggest that Rosiglitazone is mediating its effects on 
the Erk pathway via klotho-mediated suppression of Wnt5A.
We have previously shown that tumors in an aged microenvironment are more resistant to 
targeted therapy. Therefore, we examined whether increasing klotho in the 
microenvironment could affect response to PLX4720. We took aged fibroblasts, and treated 
them with rosiglitazone. We then exposed BRAF resistant melanoma cells to the media from 
the treated fibroblasts, in the presence or absence of PLX4720. Western analysis of PO4-
ERK (Figure 3d) demonstrates that rosiglitazone treatment of the fibroblasts also reduces 
PO4-ERK levels in melanoma cells. We have shown that mitochondrial ROS marks response 
to PLX4720, such that increases in mito-Sox correlate to increased resistance 
(Supplementary Figure 5a,b). As with PO4-ERK, mito-sox activity is lowered by 
rosiglitazone in melanoma cells incubated with aged fibroblasts, both in the presence and 
absence of PLX4720 (Figure 3e, Supplementary Figure 5c–e).
Taken together these data suggested that targeting klotho in both the melanoma cells and the 
microenvironment in aged mice should have effects on BRAFi resistant melanomas. To test 
this hypothesis in vivo, we treated Yumm1.7BR resistant cells with rosiglitazone or klotho, 
in the presence and absence of PLX4720 and demonstrated that these treatments decreased 
Wnt5A (Supplementary Figure 5f). Yumm1.7BR cells were injected subcutaneously into 
aged mice. Treatment with PLX4720 alone did not affect tumor growth compared to 
controls, whereas treatment with rosiglitazone alone, and the combination of rosiglitazone 
and PLX4720, impeded the rate of tumor growth (Figure 3f). The combination was not more 
effective than rosiglitazone alone. To determine if these results differed in young mice, we 
repeated the identical experiments in 8-week old mice. In young mice, Yumm1.7BR cells re-
acquired sensitivity to PLX4720, in keeping with previous data from our lab that indicated 
that melanoma cells are more sensitive to BRAFi in a young microenvironment (18). 
Intriguingly, treating young mice with rosiglitazone alone accelerated tumor growth; 
however, rosiglitazone + PLX4720 decreased tumor burden compared to PLX4720 alone 
(Figure 3g). To assay whether klotho was differentially increased in Yumm1.7BR cells in 
rosiglitazone-treated aged vs. young mice, we examined the serum of mice for klotho 
expression, and stained the tumors for klotho. In aged mice, klotho expression is low in 
Yumm 1.7BR tumors and in serum, and klotho increases in aged mice upon treatment with 
rosiglitazone (Figure 3h, left). In young mice however, klotho is high at baseline in both the 
tumor and mouse serum, and elevated even further by rosiglitazone treatment (Figure 3h, 
right). These data indicate that rosiglitazone may be a unique therapy for older patients, and 
while it cannot re-sensitize melanoma cells to vemurafenib, it can still reduce tumor burden, 
both in BRAF-inhibitor sensitive and resistant cells in aged animals. Rosiglitazone may be a 
viable alternate strategy to reduce tumor burden in older patients who have developed 
resistance to BRAF inhibitors. Our data suggest also that since PO4-Erk is reduced by direct 
treatment of melanoma cells with rosiglitazone, the right dosing schedule of rosiglitazone 
and PLX4720 may provide additional benefit in combination with BRAF inhibitors in young 
patients as well, which will be the subject of further study in our laboratory.
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Discussion
The role of klotho in aging has been well documented. The loss of klotho has also been 
implicated in the progression of multiple tumor types, including lung (20), cervical (21) and 
gastric cancer (22). In addition, we have shown that treating melanoma cells with 
recombinant klotho can reduce their invasion by inhibiting Wnt5A signaling, which is 
elevated in metastatic melanoma cells. We have also shown that, in addition to promoting 
metastasis, Wnt5A can increase resistance to vemurafenib. Maintaining klotho in aged 
patients then, could have the twin benefits of decreasing metastasis and inhibiting therapy 
resistance. Since klotho is lost during aging, and we have recently shown that aging 
promotes melanoma metastasis and therapy resistance (18), here we asked whether klotho 
loss in the aged microenvironment, specifically in fibroblasts, promotes Wnt5A expression 
and affects therapy resistance. In this study we confirm that klotho is decreased in the aged 
skin microenvironment, and manipulation of klotho in aged and young dermal fibroblasts 
affects Wnt5A expression in melanoma cells. We also show, for the first time, that Wnt5A 
can regulate klotho and that it does so by CAMKII-mediated suppression of PPARγ. When 
Wnt5A is absent, PPARγ activation increases transcription of klotho.
Because some anti-diabetic drugs (e.g. metformin) have activity against melanoma (23), and 
because some of these medications are PPARγ agonists, there has been much interest in the 
use of PPARγ agonists to treat cancer. However, the studies performed so far provide 
conflicting data as to whether PPARγ agonists are beneficial. In colon cancer, studies 
indicate that malignancy can be reversed by rosiglitazone, pioglitazone and other 
thiazolidinediones (TZD) (24–26), but Phase II clinical trials do not support this (27). 
Similarly, in breast cancer, late-stage tumors are not affected by TZD. However, a more 
recent study has shown that if the glitazone is administered earlier, to less aggressive tumors, 
i.e., HER2+ breast cancer, then it does have protective effects (28). In the current study, we 
identify yet another parameter that may affect response to glitazones, and that is age. We 
show that rosiglitazone can increase levels of klotho in the serum of aged mice bearing 
melanoma, and that this translates to an inhibition of tumor growth similar to treating mice 
directly with klotho. Treating BRAF inhibitor resistant cells with rosiglitazone reduces ROS 
in the mitochondria, and kills tumor cells. While we cannot claim that rosiglitazone re-
sensitizes cells to vemurafenib, because at the doses used there was no added benefit to 
rosiglitazone + PLX4720 vs. rosiglitazone alone, it is quite clear that rosiglitazone may 
prove to be effective against BRAFi resistant melanoma, when other options have failed. 
Similarly, increasing klotho with rosiglitazone inhibits the growth of both BRAFi-sensitive 
and BRAFi-resistant melanoma equally effectively in aged animals.
Increasing rosiglitazone increased klotho levels, decreased Wnt5A and decreased tumor 
burden in aged mice. However, this was not the case in young mice, and we were fascinated 
to find that treatment with rosiglitazone differed in young vs. aged mice. First, we have 
recently shown that changes in the aged microenvironment (e.g., increases in ROS and 
sFRP2) can drive increased resistance to targeted therapy (18). In that study, placing 
PLX4720-sensitive tumors in aged mice increased their ability to resist therapy. Here we 
show that the opposite is also true, i.e., that placing resistant tumors in young mice, slightly, 
but significantly, increases their sensitivity to PLX4720. Further, the combination of 
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PLX4720 and rosiglitazone is effective in young mice, and unlike in aged mice, 
rosiglitazone appears to sensitize tumors to PLX4720. We have shown in this study that 
treatment of melanoma with rosiglitazone lowers PO4-Erk levels, which may be enough in 
the young microenvironment to further sensitize melanomas to PLX4720. However, 
rosiglitazone alone is ineffective in treating resistant tumors in young animals, and actually 
increases tumor burden in young mice. The mechanism for this is not entirely clear, but may 
be due to a klotho threshold present in cells, which determines their susceptibility to 
PLX4720 and other MAPK targeting agents. In this case, endogenous levels of klotho in 
young mice may partially re-sensitize resistant tumors to targeted therapy, and increasing 
klotho with rosiglitazone in aged animals where klotho is endogenously low can decrease 
the growth of resistant tumors. However, raising klotho further in young animals does not 
serve to reduce tumor burden, presumably because klotho levels in young animals already 
surpass the threshold. In addition, increasing klotho too much may increase proliferation of 
the tumor, as klotho is known to increase cellular proliferation (29). If this is the case, as 
suggested by the accelerated tumor growth in the rosiglitazone-treated young mice, the age-
specific nature of this therapy might serve to explain some of the observed discrepancies in 
studies analyzing the role of PPARγ agonists in the therapy of breast and colon cancer. Age 
may play an important role in determining which patients should receive rosiglitazone as 
therapy for melanoma, and since klotho is secreted in the serum, it should be relatively 
simple to determine which patients might benefit from rosiglitazone therapy, and which 
would not. Understanding the role that the aged microenvironment plays in modulating cell 
fates like metastasis and therapy resistance is critical for guiding therapy in older patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
Increasing klotho via PPARγ activation using rosiglitazone may provide new and 
effective strategies for the treatment of therapy-resistant melanoma in older patients. Our 
data indicate that, contrary to the majority of conventional therapies, alternate approaches 
that target age-associated molecules may be selectively effective in aged patients.
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Figure 1. Loss of klotho in the aged microenvironment affects klotho and Wnt5A expression in 
melanoma cells
A, Immunohistochemical analysis of klotho in young and aged human skin (60X objective, 
1X digital zoom). B, qRT-PCR of klotho mRNA in young (N=6) and aged (N=4) human 
fibroblasts (two-tailed unpaired t-test, p=0.04). C, Western analysis of klotho in the media of 
young and aged human fibroblasts. D, Immunofluorescent analysis of klotho (green), 
HMB45 (red) and Dapi (blue) expression in 3D organotypic skin reconstructs built with 
young or aged fibroblasts (63X objective). E, Western analysis of Wnt5A in melanoma cells 
exposed to DMEM +/− serum, media from young fibroblasts or from aged fibroblasts. 
HSP90 was used as loading control. F, Immunofluorescent analysis of Wnt5A (green), 
HMB45 (red) and Dapi (blue) expression in 3D organotypic skin reconstructs built with 
young or aged fibroblasts (63X objective). G, Western analysis of Wnt5A in melanoma cells 
exposed to media from young fibroblasts or young fibroblasts after klotho knock-down or 
aged fibroblasts +/− recombinant klotho. HSP90 was used as loading control. H, 
Immunofluorescent analysis of klotho (green) expression in 3D organotypic skin 
reconstructs built with young fibroblasts infected with either a control shRNA lentivirus or a 
sh_klotho lentivirus (63X objective). HMB45 (red) was used as melanoma cell marker and 
Dapi (blue) was used to stain nuclei. I, Immunofluorescent analysis of Wnt5A (green) 
expression in 3D organotypic skin reconstructs built with young fibroblasts infected with 
either a control shRNA lentivirus or a sh_klotho lentivirus (63X objective).
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Figure 2. Wnt5A affects klotho expression via CAMKII mediated inhibition of PPARγ
A, Schematic of Wnt5A signaling showing activation of CAMKII, inhibition of PPARγ, and 
decrease of klotho transcription. Klotho is a sialidase and cleaves Wnt5A from syndecans at 
the cell surface, as we have previously published. B, Western analysis of active (phospho) 
and total CAMKII in melanoma cells treated with indicated dose of recombinant Wnt5A for 
16h. C, Immunofluorescent analysis of PPARγ and klotho in melanoma cells treated with 
rWnt5A (63X objective). D,qRT-PCR analysis of klotho expression in aged fibroblasts 
treated with the CAMKII inhibitor KN93 (10μM, 48h) (two-tailed unpaired t-test, 
***=p<0.001). E, Immunofluorescent analysis of PPARγ in KN93-treated aged fibroblasts 
(63X objective). F, Immunofluorescent analysis of PPARγ expression in melanoma cells 
after KN93 treatment (10μM, 48h) (63X objective). G, Immunofluorescent analysis of 
Klotho expression in melanoma cells after KN93 treatment (10μM, 48h) (63X objective). H, 
Immunofluorescent analysis of PPARγ expression in aged fibroblasts after treatment with 
PPARγ agonist Rosiglitazone (Roz) (63X objective). I, qRT-PCR analysis of klotho 
expression in aged fibroblasts treated with rosiglitazone (10μM, 48h) (two-tailed unpaired t-
test, ***=p<0.001). J, Tumor growth curves of Yumm1.7 murine melanoma cells in aged 
C57/BL6 mice, in the presence of recombinant klotho (n=3), rosiglitazone (n=5), or vehicle 
control (n=4). Tumor burden was significantly less in mice treated with recombinant mouse 
klotho or rosiglitazone. Repeated measures analysis of variance (Anova) was calculated 
between samples. Holm Sidak correction was done, ***=p=0.0002 (Day-20). K, Analysis of 
Klotho and Wnt5A levels in mouse tumors by immunohistochemistry analysis after 
treatment with rosiglitazone or vehicle control (40X objective). Data represented as +/− 
SEM.
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Figure 3. Rosiglitazone-mediated inhibition of phospho-Erk can inhibit growth of BRAF 
inhibitor resistant tumors
A, PO4-Erk, Erk, and Wnt5A protein expression examined by western blot analysis in 
BRAF sensitive (Yumm1.7, WM983B, WM793) and resistant subclones (Yumm1.7_BR, 
WM983B_BR, WM793_BR). B, Western blot analysis for PO4-Erk and Erk protein 
expression in WM983b_BR cells after treatment with rosiglitazone (10μM) for the indicated 
time period. C, Expression of PO4-Erk, Erk and Wnt5A following treatment with 
rosiglitazone in WM983b_BR cells transfected with Ctrl or Klotho siRNA. D, PO4-Erk, Erk, 
and Wnt5A protein expression examined by western blot analysis in WM983B-BR cells in 
the presence or absence of PLX4720 in conditioned media of aged fibroblasts treated with +/
− rosiglitazone. E, Operetta® analysis of mito-SOX intensity (measurement of 
mitochondrial ROS) in WM983B_BR cells in the presence or absence of PLX4720 in 
conditioned media of aged fibroblasts treated with vehicle i.e. DMSO:PBS (1:10) or 
rosiglitazone (Anova p<0.0001; two tailed unpaired t-test, ***=p<0.001). C=control; 
P=plx4720; R= rosiglitazone; R+P= Rosiglitazone + plx4720. F, Tumor growth of BRAFi 
resistant Yumm1.7BR cells in aged (52 weeks) C57/BL6mice, +/− PLX4720 and +/− 
rosiglitazone. N=5 mice/group. Repeated measures analysis of variance (Anova) was 
calculated between samples, p<0.0001. Holm Sidak correction was performed, ***=p<0.005 
(Day-18). G, Tumor growth of BRAFi resistant Yumm1.7BR cells in young (8 weeks) C57/
BL6mice, +/− PLX4720 and +/− rosiglitazone (N=7 mice/group. Repeated measures 
analysis of variance (Anova) was calculated between samples, p<0.0001. Multiple 
comparision with Holm Sidak correction was done. H, Klotho levels in aged (left two 
panels) or young (right two panels) mouse serum (western blot) or tumors 
(immunohistochemistry) after treatment with rosiglitazone or vehicle control (40X 
objective).
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